Table 3 Analysis of covariance with mean differences of outcome measures (DAS28, HAQ) between nulliparous and parous women with incident RA included in the EIRA study, at baseline and follow-up visits during the first 24 months
Outcome measure above median | ACPA-negative RA | |
|---|---|---|
18–44 years | 45–70 years | |
Beta (95 % CI), p-value | Beta (95 % CI), p-value | |
DAS28 | ||
Baseline | 0.02 (−0.58 to 0.62), p = 0.95 | −0.78 (−1.19 to −0.37), p < 0.001 |
3 months | 1.60 (0.81 to 2.40), p < 0.001 | −0.45 (−0.96 to 0.06), p = 0.96 |
6 months | 1.30 (0.48 to 2.12), p = 0.002 | −0.27 (−0.82 to 0.28), p = 0.34 |
12 months | 1.22 (0.59 to 1.85), P < 0.001 | −0.31 (−0.73 to 0.12), p = 0.16 |
24 months | 0.86 (0.18 to 1.55), p = 0.014 | −0.29 (−0.76 to 0.19), p = 0.24 |
HAQ | ||
Baseline | 0.06 (−0.23 to 0.34), p = 0.68 | −0.35 (−0.56 to −0.14), p = 0.001 |
3 months | 0.40 (0.05 to 0.74), p = 0.026 | −0.12 (−0.32 to 0.08), p = 0.24 |
6 months | 0.44 (0.13 to 0.75), p = 0.006 | −0.09 (−0.30 to 0.12), p = 0.38 |
12 months | 0.43 (0.16 to 0.69), p = 0.002 | −0.02 (−0.20 to 0.16), p = 0.80 |
24 months | 0.48 (0.14 to 0.82), p = 0.006 | −0.17 (−0.38 to 0.05), p = 0.13 |